CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Simvastatin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02743364
NCT02743364Phase 2Completed

Statin Therapy to Reduce the Risk of Recurrent Pancreatitis

National Cancer Institute (NCI)·interventional·Posted Apr 19, 2016·Updated Dec 13, 2022

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Placebo Administration, and 3 other interventions for Acute Pancreatitis. Completed, enrolled 8 participants across 5 sites.

Detailed Summary

This randomized phase II trial studies how well simvastatin works in reducing pancreatitis (the inflammation of the pancreas) in patients with pancreatitis that occurs more than once (recurrent), has worsened quickly (acute), or has persisted or progressed over a long period of time (chronic). Simvastatin may decrease the inflammation of the pancreas by modulating the immune response responsible for inflammation. It is not yet known if simvastatin may be an effective treatment for pancreatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 19, 2016
Enrollment StartSep 19, 2016
Primary CompletionOct 14, 2019
Study CompletionMay 11, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.2 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Placebo Administrationother

Given PO

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies

Simvastatindrug

Given PO